A Phase 3, Single-Arm, Open-label Clinical Study to Evaluate the Safety and Immunogenicity of 4 Doses of V114 Administered to Healthy Infants in South Korea
Latest Information Update: 17 Apr 2024
At a glance
- Drugs V 114 (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Acronyms PNEU-PED-KOR
- Sponsors Merck Sharp & Dohme
- 09 Nov 2022 Status changed from active, no longer recruiting to completed.
- 24 Aug 2022 Planned End Date changed from 5 Dec 2022 to 7 Nov 2022.
- 24 Aug 2022 Planned primary completion date changed from 5 Dec 2022 to 7 Nov 2022.